Biopharmaceutical Companies Benefit From Positive Data on Anti-TIGIT Therapy
Shares of several biopharmaceutical companies developing anti-TIGIT cancer therapies experienced a surge in premarket trading following an unexpected disclosure by Roche AG. The disclosure involved interim data from a study…